## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims:

Claims 1-37. (Canceled)

38. (Currently Amended) A compound of the formula (I):



(I)

wherein:

$A_1$ represents a hydrogen atom, a group selected from a substituent group β optionally having 1 or 2 groups selected from a substituent group α, or a phenyl or heteroaryl group, which optionally have 1 or 2 groups selected from a substituent group γ;

j is 1, and the formula (III-1):



(III-1)

in the formula (I) represents a group of the formula:



wherein $A_2$ is selected from the definitions of $A_1$;

k is 0, and the formula (III-2):



(III-2)

in the formula (I) represents a double bond;

one of $W_1$ and $W_2$ is $A_4$, wherein $A_4$ is a hydrogen atom or a lower alkyl group, and the other of $W_1$ and $W_2$ is E-O-W, or $W_1$ may be E-O-W and $A_2$-C=C-$W_2$ may together form a benzene ring or a heteroaryl ring having from 1 to 3 of the same or different hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom (the benzene ring and the heteroaryl ring may be substituted with a nitro group, a hydroxy group, a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, an alkanoylamino group);

E represents a phenyl group optionally having from 1 to 3 groups selected from a substituent group δ, or a 5- or 6-membered monocyclic aromatic heterocyclic group having 1 to 3 of the same or different hetero atoms selected from a group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or represents a condensed-cyclic aromatic heterocyclic group that the monocyclic aromatic heterocyclic group forms together with an aryl group;

W represents the formula (II-1):



(II-1)

the formula (II-2):



(II-2)

or the formula (II-3):




(II-3)

wherein $G_1$ and $G_2$ may be the same or different, each representing a lower alkyl group (the lower alkyl group may be further substituted with a halogen atom) or a cycloalkyl group, or $G_1$ and $G_2$ form, together with the nitrogen atom adjacent to $G_1$ and $G_2$, a 5- to 8-membered aliphatic hetero-ring (the hetero-ring may have, in the ring, 1 or 2 groups of a lower alkyl group optionally substituted with a halogen atom or a halogen atom) or a bicyclo-ring; m1 indicates an integer of from 2 to 4; m2 and m3 each indicate an integer of from 1 to 3; $(CH_2)$m1 in the formula (II-1) may be further substituted with a lower alkyl group having from 1 to 3 carbon atoms;

wherein substituent group α is selected from the group consisting of:

an amino group, a nitro group, a cyano group, a hydroxy group, a halogen atom, a lower alkylsulfonyl group, a lower alkyl group (the lower alkyl group may be substituted with a halogen atom), a lower cycloalkyl group (the lower cycloalkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower cycloalkoxy group (the lower cycloalkoxy group may be substituted with a halogen atom), an aryloxy group, an alaryloxy group, an aryl group, a heteroaryl group, a mono-lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a lower alkylcarboxamido group, an arylcarboxamido group, a heteroarylcarboxamido group, an alkanoyl group, and an alkylthio group;

wherein substituent group β is selected from the group consisting of:

an amino group, a lower alkylsulfonyl group, a lower alkyl group, a lower cycloalkyl group, a lower alkoxy group, a lower cycloalkoxy group, the lower alkyl group being optionally substituted with a halogen atom, a lower cycloalkyl group (the cycloalkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower cycloalkoxy group (the lower cycloalkoxy group may be substituted with a halogen atom), a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group;

wherein substituent group γ is selected from the group consisting of:

an amino group, a nitro group, a cyano group, a hydroxy group, a lower alkylsulfonyl group, a halogen atom, a lower alkyl group (the lower alkyl group may be substituted with a halogen atom), a lower cycloalkyl group (the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom or a hydroxy group), a lower cycloalkoxy group (the lower alkyl group may be substituted with a halogen atom), an aryloxy group, an alaryloxy group, an aryl group, a heteroaryl group, a mono-lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a lower alkylcarboxamido group, an arylcarboxamido group, a heteroarylcarboxamido group, an alkanoyl group, an alkylthio group, an alkoxycarbonylamino group, an alkylsulfonylamino group, an arylsulfonylamino group, and an alkylaminosulfonyl group or an arylaminosulfonyl group;

wherein substituent group δ is selected from the group consisting of:

a halogen atom, a nitro group, a lower alkyl group, a halo-lower alkyl group, a hydroxy group, a hydroxy-lower alkyl group, a cyclo-lower alkyl group, a lower alkenyl group, a hydroxyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylamino group, a di-lower alkylamino group, a lower alkylthio group, a carboxyl group, a lower alkanoyl group, and a lower alkoxycarbonyl group;

or a pharmaceutically acceptable salt thereof.

39. (Currently Amended) The compound of Claim 38 wherein $A_1$ is a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group, a phenyl group, a pyridyl group, a carbamoyl group, a mono- or di-lower alkylcarbamoyl group, and $A_2$~~,~~ ~~$A_3$~~ and $A_4$ each are independently a hydrogen atom or a lower alkyl group.

40. (Previously Presented) The compound of Claim 38 wherein one of $W_1$ and $W_2$ is $A_4$, and the other is E-O-W; or $W_1$ is E-O-W, and $A_2$-C=C-$W_2$ together forms a benzene ring or a heteroaryl ring having 1 or 2 nitrogen atoms in the ring.

41. (Previously Presented) The compound of Claim 38 wherein E is a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group or a pyrazinyl group.

42. (Previously Presented) The compound of Claim 38 wherein E is a phenyl group or a pyridyl group.

43. (Previously Presented) The compound of Claim 38 wherein E is a phenyl group.

44. (Previously Presented) The compound of Claim 38 wherein W is of the formula (II-1) or the formula (II-3).

45. (Previously Presented) The compound of Claim 38 wherein the formula (I) is selected from the following formula (I-0), (I-2), (I-3) and (I-4):




(I-0)




(I-2)




(I-3)




(I-4)

wherein:

the ring A represents a benzene ring or a heteroaryl ring having 1 or 2 nitrogen atoms in the ring (wherein the benzene ring and the heteroaryl ring is unsubstituted or substituted with a nitro group, a hydroxyl group, a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, or an alkanoylamino group).

46. (Previously Presented) The compound of Claim 44 wherein the ring A is a benzene ring or a pyridine ring.

47. (Previously Presented) A compound of the formula (I-0):




(I-0)

wherein:

$A_1$ represents a hydrogen atom, C(1-6)alkyl group optionally substituted with halogen atom, a pyridyl group, a phenyl group, a mono-C(1-6)alkylcarbamoyl group, a di-C(1-6)alkylcarbamoyl group, or a piperidin-1-yl-carbonyl group;

$A_2$ represents a hydrogen and $W_2$ represent $A_4$, or $A_2$ and $W_2$ together form a ring A,

wherein ring A is selected from the group consisting of: a benzene ring, a pyridine ring, a thiophene ring, a furan ring and a pyrazine ring;

$A_4$ is selected from the definitions of $A_1$;

E represent a phenyl, a pyridyl, a pyrimidinyl or a pyridazinyl group;

W represents the formula (II-1):



(II-1)

the formula (II-2):



(II-2)

or the formula (II-3):



(II-3)

wherein $G_1$ and $G_2$ may be the same or different, each representing a C(1-6)alkyl group wherein the alkyl group may be further substituted with a halogen atom, or a C3 or C4 cycloalkyl group, or $G_1$ and $G_2$ form, together with the nitrogen atom adjacent to $G_1$ and $G_2$, a 5- to 8-membered aliphatic hetero-ring, wherein the hetero-ring may have, in the ring, 1 or 2 groups of a C(1-6)alkyl group optionally substituted with a halogen atom, or the hetero-ring may have, in the ring, 1 or 2 groups of a halogen atom;

m1 indicates an integer which is 2, 3 or 4;

m2 and m3 each indicate an integer which is 1, 2 or 3;

$(CH_2)$m1 in the formula (II-1) may be further substituted with an alkyl group having from 1 to 3 carbon atoms;

or a pharmaceutically acceptable salt thereof.

48. (Previously Presented) The compound of Claim 47 wherein E is a phenyl or a pyridyl group.

49. (Previously Presented) The compound of Claim 48 wherein E is a phenyl group.

50. (Previously Presented) The compound of Claim 47 wherein $A_2$ is a hydrogen atom and $W_2$ represents $A_4$.

51. (Previously Presented) The compound of Claim 47 wherein $A_2$ and $W_2$ together form the ring A.

52. (Previously Presented) The compound of Claim 51 wherein the ring A is a benzene ring or a pyridine ring.

53. (Previously Presented) A compound which is selected from the group consisting of:

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine,
3-tert-butyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine,
7-methyl-3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-methyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3,6-dimethyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

6-methyl-3-phenyl-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
3-phenyl-6-[6-(3-piperidin-1-ylpropoxy)-pyridin-3-ylmethoxy]-[1,2,4]triazolo[3,4-a]phthalazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-3-yl)-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-2-yl)-[1,2,4]triazolo[3,4-a]phthalazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-trifluoromethyl-[1,2,4]triazolo[3,4-a]phthalazine,
3-tert-butyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,6-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,6-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine,
6-{4-[3-(2,6-dimethylpiperizin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
N-methyl-6-[4-(3-piperidin-1-ylpropoxy)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide,
3-(piperidin-1-ylcarbonyl)-6-[4-(3-piperidin-1-ylpropoxy)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-methylpiperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(3S)-3-fluoropyrrolidin-1-yl]propoxy}-phenyl)-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(3-methylpiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(4-fluoropiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(3-fluoropiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(2R)-(2-methylpyrrolidin-1-yl]propoxy)-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(2S)-(2-methylpyrrolidin-1-yl]propoxy)-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
N,N-dimethyl-6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy)-phenyl}-[1,2,4]triazolo[3,4-a]phthalazine-3-carboxamide,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-(4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-(4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-(4-{3-[(2R)-3-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-(4-{3-[(2R)-3-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-[1,2,4]triazolo[3,4-a]phthalazine, and
6-{6-[(3S)-3-piperidin-1-ylpropoxy]pyridin-3-yl]-[1,2,4]triazolo[3,4-a]phthalazine,
or a pharmaceutically acceptable salt thereof.

54. (Previously Presented) A pharmaceutical composition which comprises the compound of Claim 38 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

55. (Previously Presented) A pharmaceutical composition which comprises the compound of Claim 47 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

56. (Previously Presented) A pharmaceutical composition which comprises the compound of Claim 53 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.